clarity please, page-3

Thanks, having a more than passing knowledge in neuropsychology I have always known this will be a slow burn until Phase II trial data, it's also what grabbed my attention a few years ago. To make Phase II is rare enough as it is in this particular drug pipeline ('3dr gen' drugs) in this category are now over 20-30 years old. In 1987 when Eli Lilly received FDA approval for Prozac annual revenue averaged 3 billion just from that drug alone, that of course disintegrated when patent expired, now this is the same company that created insulin so had a vast range of drug profits, BNO when / if it goes and lives up to its drug profile data will do the same - "The BCN210 (insert market name here) Generation" may be as synonymous as "The Prozac Generation".